Journal
ONCOTARGET
Volume 6, Issue 12, Pages 9756-9765Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.3395
Keywords
Rspo1; glioma; radiation
Categories
Funding
- National Nature Science Foundation of China [31171219, 81271213, 81471294, 81271214, 81210108045]
- Natural Science Foundation of Guangdong Province [S2012010008222]
- Science and Technology Innovation Fund of Guangdong Medical College [STIF 201101]
- Creative scientific and technological project - Science and Technology Bureau of Harbin, China [2012RFXXS069]
- Natural Science Foundation of Heilongjiang Province, China [D201257]
Ask authors/readers for more resources
Although radiation therapy is the most effective postoperative adjuvant treatment, it does not substantially improve the long-term outcomes of glioma patients because of the characteristic radioresistance of glioma. We found that R-Spondin1 (Rspo1) expression was elevated in high-grade gliomas and was associated with worse overall survival and disease-free survival. Rspo1 expression was also associated with reduced survival rates in glioma patients after treatment with radiotherapy and temozolomide (RT-TMZ). Importantly, Rspo1 was dramatically upregulated after radiation treatment in patients with glioma. Rspo1 silencing by shRNA potentiated glioma cell death upon radiation treatment. In a xenograft nude mouse model, combining radiation and silencing of Rspo1 potentiated tumor growth inhibition. Thus, combining radiotherapy with silencing of Rspo1 is a potential therapeutic approach.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available